R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the use of the standard treatment R-CHOP plus the anti-VEGF drug,
bevacizumab and whether this treatment is feasible in patients with stage II, III and IV
diffuse large B cell lymphoma (DLBCL).